Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chai...
DexCom: Revenue Up, EPS Misses Mark
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, whi...
DexCom (DXCM) Misses Q4 Earnings Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to un...
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
DexCom Inc. DXCM is off to a strong start in 2025, with its stock rallying 5.7% following the release of its preliminary results for the fourth quarter and fiscal 2024 on Jan. 13, 2025. The compan...
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valu...
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher.
Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massiv...
DexCom: Brighter 2025 From Stelo Ramp
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with tempor...
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical s...
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.
DexCom and OURA Ink Partnership for Metabolic Health Innovation
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
Related Companies